Detalhe da pesquisa
1.
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Gastric Cancer
; 24(4): 926-936, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651195
2.
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Gastric Cancer
; 24(2): 445-456, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970266
3.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Ther Adv Med Oncol
; 15: 17588359231157641, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895850
4.
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.
Thromb Haemost
; 122(10): 1653-1661, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35381615
5.
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Ther Adv Med Oncol
; 13: 17588359211019672, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34211587
6.
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
PLoS One
; 15(7): e0235848, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32735623
7.
Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma.
Front Genet
; 10: 439, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31156702
8.
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer.
Thromb Haemost
; 119(11): 1849-1859, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31461750